Collectively, these results demonstrate that the ASAH1-driven ceramide metabolism pathway can be inhibited pharmacologically to treat melanoma and enhance outcomes when combined with other targeted therapeutics, such as BRAF kinase inhibitors. This evidence concerns the gene ASAH1 and melanoma.